We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R DLBCL CAR T‐Naive and CAR T‐eligible patients: An Indirect Comparison.
- Authors
Thieblemont, C.; Fox, C. P.; Wang, A.; Sail, K.; Alshreef, A.; Moran, M.; Mutebi, A.; Blaedel, J.; Chirikov, V.; Salles, G.
- Abstract
Patients in EPCORE NHL-1 with prior CAR T therapy were excluded as ZUMA-1 included only patients without prior CAR T therapy. Efficacy of Subcutaneous Epcoritamab versus Axi-cel in R/R DLBCL CAR T-Naive and CAR T-eligible patients: An Indirect Comparison B Introduction: b Epcoritamab, an off-the-shelf, subcutaneous CD3xCD20 T-cell-engaging bispecific antibody that redirects T cells to eliminate malignant CD20+ B cells, showed single-agent efficacy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) with a manageable safety profile.
- Subjects
DIFFUSE large B-cell lymphomas
- Publication
Hematological Oncology, 2023, Vol 41, p453
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_334